BIO
Bio-Rad Laboratories, Inc.
BIO's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over BIO overall, supported by stronger fundamentals and stronger modeled upside.
BIO Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Healthy | |
| Strong |
BIO's cash flow and balance sheet are currently healthy, and its revenue is stable, but its profitability is under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
BIO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 4.5x | $169 | -54% |
| Fair | 7.4x | $280 | -24% |
| Current | 9.8x | $370 | — |
| Expensive | 31x | $1,157 | +212% |
| Forward | 35x | $370 | — |
Historical ranges are pointers, not guarantees.
BIO's PE is 9.8x, but its earnings don't support one, so it isn't a reliable read right now.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY has the edge over BIO in the historical PE scenario, which offers more potential upside but is not a forecast.
BIO Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect BIO's earnings to grow and its profitability to improve, with its revenue holding steady.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over BIO on the outlook, with more favorable valuation and revenue expectations.
BIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $10.69 | -72% |
| Q3 2026 | $37.91 | +$62.22 |
| Q2 2026 | $8.19 | -30% |
| Q1 2026 | $6.01 | +$82.21 |
| Q4 2025 | $27.85 | +$92.89 |
| Q3 2025 | -$24.31 | +$3.02 |
| Q2 2025 | $11.73 | +$58.76 |
| Q1 2025 | -$76.20 | -$65.84 |
| Q4 2024 | -$65.04 | -$43.55 |
BIO has returned to profit: it earned $37.91 per share over the past year, after losing money the year before. Its recent earnings include one-off gains.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over BIO on earnings, with more consistent year-over-year improvement.
BIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $656.4M | +0.5% |
| Q2 2026 | $651M | -0.1% |
| Q1 2026 | $592.1M | +1.1% |
| Q4 2025 | $693.2M | +3.9% |
| Q3 2025 | $653M | +0.5% |
| Q2 2025 | $651.6M | +2.1% |
| Q1 2025 | $585.4M | -4.2% |
| Q4 2024 | $667.5M | -2% |
BIO's revenue fell from its 2020 peak and has held roughly level since: $656M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.6% | -18 points |
| Q2 2026 | 11% | -0.7 points |
| Q1 2026 | 5.8% | +1.7 points |
| Q4 2025 | -17% | -26 points |
| Q3 2025 | 10% | +0.1 points |
| Q2 2025 | 12% | -4.1 points |
| Q1 2025 | 4% | -3.3 points |
| Q4 2024 | 8.7% | -5.3 points |
BIO's operating margin was −7.6% last quarter, down 18 points from the same quarter a year ago, near the bottom of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over BIO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over BIO on profitability, with a higher operating margin.
BIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $65.2M | -27% |
| Q2 2026 | $66.7M | -5.8% |
| Q1 2026 | $78.1M | -18% |
| Q4 2025 | $119.1M | +47% |
| Q3 2025 | $89.2M | -28% |
| Q2 2025 | $70.8M | +28% |
| Q1 2025 | $95.5M | +222% |
| Q4 2024 | $81.2M | +109% |
BIO still generates free cash flow, though less than at its 2020 peak: $329M over the past year.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over BIO on cash flow, with more consistent year-over-year improvement.
BIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +131K shares |
| 1 year | +0.1% | +22K shares |
| 3 years | -7.8% | -2.3M shares |
| 5 years | -11% | -3.3M shares |
| Available history | -11% | -3.2M shares |
BIO has 27M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $31.5M |
| Q1 2026 | $47.8M |
| Q4 2025 | — |
| Q3 2025 | $53.4M |
| Q2 2025 | $140.2M |
| Q1 2025 | $101.9M |
| Q4 2024 | $14,000 |
BIO spent $79M buying back its own shares over the past year, down 73% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over BIO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
BIO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2020 | -1.6x | Net Cash |
| Q4 2019 | -1.8x | Net Cash |
BIO has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
BIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.1 | Neutral |
| Stochastic | 66.5 | Neutral |
BIO's weekly RSI is 59 (neutral) and its Stochastic is 67 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
BIO PE vs Healthcare Sector
| Metric | BIO | Sector median | Relative |
|---|---|---|---|
| PE | 9.8x | 26x | 62% below |
| PE % | 67 | 29 | 38 pts above |
BIO has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
BIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $370.5 | 0% below |
| 20 week MA | $355.5 | 4.2% above |
| 50 week MA | $314.3 | 18% above |
| 100 week MA | $297.5 | 25% above |
| 200 week MA | $326.1 | 14% above |
BIO has slipped below its 8-week average, but it's still above the other four, and 14% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over BIO on trend strength, trading above more of its moving averages.
BIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $368.4 | $575.1 | +56% |
| 2021 | $575.1 | $746.3 | +30% |
| 2022 | $746.3 | $412.7 | -45% |
| 2023 | $412.7 | $322.9 | -22% |
| 2024 | $322.9 | $330.9 | +2.5% |
| 2025 | $330.9 | $303.9 | -8.2% |
| 2026 YTD | $303.9 | $370.5 | +22% |
BIO has finished lower in three of the last six years. It's up 22% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over BIO on returns for 2026, with the stronger performance.